ESR1 and ovarian cancer: Based on our data, the use of steroid-resembling estrogen analogues in MHT, which have a higher affinity to ERα than ERβ, would increase the risk of ovarian cancer by up-regulating sema 4D expression and accelerating the multiplication of ovarian cells.